No significant differences were observed in patient age, patient sex, gender matching between donors and recipients, underlying disease, donor source, conditioning regimen, serotherapy, KIR-L mismatch, and dose of CD34+, CD3+, or CD56+ cells in allografts between the GVHD group and the non-aGVHD group. This evidence concerns the gene CD34 and graft versus host disease.